Back to Peptide Pedia
Cognitive & Nootropic
Emerging Research

Omberacetam

NOO

Dipeptide nootropic compound.

Also known as: Noopept, GVS-111

Research dose range10–30 mg daily (research models)
Route studiedOral / sublingual
Study durationDaily, multi-week studies
StorageRoom temperature (dry)

Overview

Omberacetam (Noopept) is a dipeptide nootropic studied in memory, neuroprotection, and cognition research.

Key research findings

A peptide-derived nootropic (the proline-containing dipeptide analog of piracetam) developed in Russia and marketed there as Noopept. Research reports memory enhancement, neuroprotection, and increased BDNF/NGF expression at very low doses relative to classic racetams.

Mechanism of action

Studied for modulating acetylcholine and glutamate (AMPA/NMDA) signaling and increasing BDNF and NGF expression.

Molecular information

Weight318.4 Da
LengthDipeptide derivative
TypeProline-containing piracetam analog
Amino-acid sequenceN-phenylacetyl-L-prolylglycine ethyl ester

Peptide-derived but orally stable; far more potent by weight than piracetam.

Pharmacokinetics

Peak: ~0.25–0.5 hoursHalf-life: ~0.5 hours (active metabolite cycloprolylglycine longer)Cleared: ~24 hours
Peak · 1hHalf-life · 4h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

  • Memory and cognition research
  • Neuroprotection studies
  • Nootropic-mechanism investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Conservative referenceAmount: 10 mgFrequency: 1–2× dailyRoute: Oral
Standard referenceAmount: 20–30 mgFrequency: Daily (divided)Route: Oral

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

  1. Week 1–2

    Memory and focus changes reported; BDNF/NGF upregulation noted in models.

  2. Week 2–8

    Cumulative cognitive and neuroprotective effects reported with continued use.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

Semax

Complementary nootropic pathways.

Compatible

Bromantane

Complementary cognition/energy mechanisms.

Compatible

P21

Complementary neurogenic/BDNF pathways.

Compatible

Quality indicators

Consistent oral form

Research material is typically a capsule or tablet; verify labeled concentration.

Dry storage

As a stable small molecule, it does not require cold-chain handling.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

  • Generally reported as well tolerated; irritability or headache are occasionally reported.
  • Most clinical evidence originates from Russian research and is less replicated elsewhere.

References & further reading

Noopept (omberacetam): cognition and neuroprotection (review)

Human/preclinicalracetam analogBDNF/NGF

Review of omberacetam's memory-enhancing, neuroprotective, and neurotrophic effects.

View study

Topics

nootropicmemoryneuroprotection

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level
Emerging Research

Active but early-stage research; evidence still developing.

Quick reference
Dose range10–30 mg daily (research models)
RouteOral / sublingual
DurationDaily, multi-week studies
StorageRoom temperature (dry)
Half-life~0.5 hours (active metabolite cycloprolylglycine longer)
Catalogue status

This compound is part of our educational reference and is not currently stocked. Browse the catalogue for available research-grade peptides.

Browse catalogue